Viral vector production with the HEK293 Media Survey Panel
Human embryonic kidney (HEK293) cells are the most commonly used cell line to produce viral vectors for gene therapy.
Due to the complexity of their production and purification, viral vectors can be very expensive to produce. Choosing the proper media in a scale-down model for each cell line and process can improve yield and lower production costs.
HEK293 Media Survey Panel is a curated panel of six growth media and three feed supplements of high-quality, scalable, CD HEK media, designed for a quick and efficient process to discover the optimal media for increased titers and VG/capsid ratios for therapeutic development.
What will you learn?
- How to optimize your HEK293 media for cell and gene therapy and viral vector-based vaccine applications
- How HMSP growth media can significantly improve growth and production of AAV and AAV2 serotypes
- The advantage of choosing the proper scale-down model for each cell line to improve yield and lower production costs
Who may this interest?
- Process Development Scientist, Bioprocessing/Bioproduction
- Research Director, Bioprocessing/Bioporduction
- Director R &D, Cell Line Development / Cell and Gene Therapy
- Scientist, Cell and Gene Therapy, Biologics Manufacturing
- Supply chain/ procurment managers , Cell and Gene Therapy
Your Speaker
Omid Taghavian, PhD
Senior Scientist II
FUJIFILM Irvine Scientific
Omid Taghavian, is a Senior Scientist II with FUJIFILM Irvine Scientific, where he leads the Media Development and Optimization group for Gene Therapy in R&D.
With over 10 years of experience in the biotechnology industry, he has focused extensively on infectious disease biomarkers and vaccine discovery and development. Omid holds a PhD and Master of Science in Molecular Biotechnology.
This webinar was recorded on Thursday 27th October 2022
In association with
